Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: Results from two replicate 48-week studies

International Journal of COPD

Volumn 9, Issue , 2014, Pages 697-714

  Koch, Andrea ^a   Pizzichini, Emilio ^b   Hamilton, Alan ^c   Hart, Lorna ^c   Korducki, Lawrence ^d   De Salvo, Maria Cristina ^e   Paggiaro, Pierluigi ^f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e Centro Médico Dra De Salvo Fundación Respirar   (Argentina)

^f UNIVERSITY OF PISA   (Italy)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Dyspnea; Long acting beta2 agonist

Indexed keywords

FORMOTEROL; OLODATEROL; PLACEBO; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; INHALER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SEX RATIO; SPIROMETRY; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL CAPACITY; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AREA UNDER CURVE; BENZOXAZINES; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904071261     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S62502     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed July 15, 2013.
2. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Bronchodilators. Proc Am Thorac Soc. 2007;4(7):526-534.
3. Anderson GP. Formoterol: pharmacology, molecular basis of ago-nism, and mechanism of long duration of a highly potent and selective beta 2- adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26): 2145-2160.
4. Ball DI, Brittain RT, Coleman RA, et al. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991;104(3):665-671.
5. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG, on behalf of a Dutch study group. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8(9):1506-1513.
6. Littner MR, Ilowite JS, Tashkin D P, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1): 1136-1142.
7. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin. 2009; 25(2):463-470.
8. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50(10):1346-1356.
9. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review. Chest. 2012;142(5):1104-1110.
10. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53-62.
11. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600-609.
12. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666-672.
13. O'Byrne PM, van der Linde J, Cockcroft DW, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124(6):1217-1221.
14. van Noord JA, Korducki L, Hamilton A, Koker P. Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients. Am J Respir Crit Care Med. 2009;179: A6183 (abstract).
15. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord J. Comparison of 24-hour FEV1 profle for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPD. Am J Respir Crit Care Med. 2012;185:A2930 (abstract).
16. O'Byrne PM, D'Urzo T, Gahlemann M, Hart L, Wang F, Beck E. Dose-fnding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma. Am J Respir Crit Care Med. 2012;185:A3963 (abstract).
17. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientifc_guideline/2012/08/WC500130880.pdf. Accessed August 7, 2013.
18. Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):234-238.
19. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758.
20. Jones P W, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Resp Med. 1991;85(Suppl B):25-31.
21. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
22. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 36 NDA datasets. J Biopharm Stat. 2009;19(2):227-246.
23. Little RJ, Wang Y. Pattern-mixture models for multivariate incomplete data with covariates. Biometrics. 1996;52(1):98-111.
24. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education, National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington DC: National Academies Press; 2010.
25. Hogan J W, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med. 2004;23(9):1455-1497.
26. Ichinose M, Takizawa A, Izumoto T, Fukuchi Y. Effcacy of 4 weeks' once-daily treatment with olodaterol (BI 1744), a novel long-acting β2-agonist, in Japanese patients with COPD. Am J Respir Crit Care Med. 2012;185:A2931 (abstract).
27. Koch A, Pizzichini E, Hamilton A, et al. Lung function effcacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies. Eur Respir J. 2013; 42 (Suppl 57):146s, P764 (abstract).
28. Ferguson G, Feldman G, Hofbauer P, et al. Lung function effcacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies. Eur Respir J. 2013;42 (Suppl 57):5s, 187 (abstract).
29. Lange P, Aumann J-L, Derom E, et al. The 2 4-h FEV1 time profle of olo-daterol QD delivered via Respimat® in COPD: Results from two 6 -week studies. Eur Respir J. 2013;42(Suppl 57):982s, 4635 (abstract).
30. McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodat-erol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis. Eur Respir J. 2013;42(Suppl 57):749s, P3633 (abstract).
31. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord JA. Comparison of 24-hour FEV1 profle for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2 agonist, in patients with COPD. Poster A2930 presented at the 103rd Annual International Conference of the American Thoracic Society, San Francisco, CA, USA, May 18-23, 2012.
32. Feldman G, Bernstein J, Hamilton A, Nivens C, Wang F, LaForce C. The 24-hour FEV1 time profle of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies. Abstract 749A presented at CHEST, Chicago, IL, USA, October 26-31, 2013.
33. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic beneft of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 4 8-week studies. Eur Respir J. 2013;42(Suppl 57):145s, P763 (abstract).
34. Maltais F, Kirsten A, Hamilton A, De Sousa D, Wang F, Decramer M. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies. Abstract 748A presented at CHEST, Chicago, IL, USA, October 26-31, 2013.
35. Tashkin D P, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
36. Bouyssou T, Schnapp A, Casarosa P, Pieper MP. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bron-choprotection in pre-clinical models. Am J Respir Crit Care Med. 2010;181:A4445 (abstract).
37. Bouyssou T, Casarosa P, Pieper M, Schnapp A, Gantner F. Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs. Eur Respir J. 2011;38(Suppl 55):613s, 3451 (abstract).
38. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fxed dose combination compared with tiotropium in COPD patients. Eur Respir J. 2010;36(Suppl 54):1014s, 5557 (abstract).
39. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-fnding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD. Abstract 2882 presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1-5, 2012.